Senar Gunenc

Senar Gunenc

Auto-generated profile, based on publicly available information

Senar Gunenc

Department of Radiation Oncology, Yedikule Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 December 2024 in Cyprus Turkish Journal of Psychiatry and Psychology
Verified
Journal Article
Closed access
ESEsra Savas
Esra Savas
GCGulsen Filazoglu Cokluk
Gulsen Filazoglu Cokluk
SGSenar Günenç
Senar Günenç
This study investigated the relationships among self-compassion, prolonged grief, and post-cancer growth in patients with lung cancer. With a quantitative and cross-sectional research model, 100 patients with lung cancer from the Medical Oncology Clinic of Yedikule Hospital were evaluated. Data were collected using sociodemographic and medical forms, the Prolonged Grief Disorder Scale, the Cancer Empowerment Scale, and the Self-Compassion Scale. The results showed that there were significant negative correlations between prolonged grief and cancer empowerment and self-compassion. In contrast, self-compassion showed significant positive correlations with cancer empowerment and its dimensions of personal power and social support. These findings suggest that high self-compassion is associated with reduced prolonged grief and increased empowerment, highlighting its importance in the psychological well-being and adjustment of lung cancer patients. This study emphasizes the need for psychological interventions that promote self-compassion to improve quality of life and treatment adherence in this patient population.

8 May 2026 in Medicine
Verified
Journal Article
Open access
SSSermin Dinc Sonusen
Sermin Dinc Sonusen
ZIZehra Sucuoglu Isleyen
Zehra Sucuoglu Isleyen
NSNaime Afsar Satis
Naime Afsar Satis
MYMesut Yilmaz
Mesut Yilmaz
BDBekir Doğan
Bekir Doğan
MAMuhammed Mustafa Atci
Muhammed Mustafa Atci
Extensive-stage small cell lung cancer (ES-SCLC) in older adults is associated with poor outcomes, and optimal management in this population remains challenging. This study aimed to identify clinical and treatment-related factors associated with survival in patients aged ≥70 years with ES-SCLC. A retrospective multicenter cohort study included 135 older adults (aged ≥70 years) diagnosed with ES-SCLC across 3 tertiary centers. All patients received at least 1 cycle of platinum–etoposide–based chemotherapy. Demographic, clinical, and treatment variables – including metastatic sites, number of chemotherapy cycles, thoracic radiotherapy (TRT), prophylactic cranial irradiation, and palliative radiotherapy to extracranial metastases – were collected. Survival outcomes were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors for progression-free survival and overall survival (OS) were evaluated using Cox proportional hazards regression models. The median age was 73.2 years; 88.1% of patients were male. The objective response rate was 69.9%. Median progression-free survival and OS were 7.1 and 8.3 months, respectively (95% CI: 6.09–8.17 and 7.67–8.93). In multivariate analysis, Eastern Cooperative Oncology Group performance status ≥2 ( P <.001), liver metastases ( P = .006), fewer than 4 chemotherapy cycles ( P <.001), absence of prophylactic cranial irradiation ( P = .028), and lack of palliative radiotherapy to extracranial metastases ( P <.001) were independently associated with shorter OS. TRT did not retain statistical significance in multivariate analysis. Only 34.1% of patients received second-line therapy. The 1-year and 2-year OS rates were 33% and 12%, respectively. Fit older adults (Eastern Cooperative Oncology Group performance status 0–1) may derive meaningful survival benefit from multimodal treatment strategies. Treatment decisions should be individualized based on functional status rather than chronological age alone. Prospective studies incorporating comprehensive geriatric assessment are warranted.

1 April 2026 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SSSermin Dinc Sonusen
Sermin Dinc Sonusen
ZIZehra Sucuoglu Isleyen
Zehra Sucuoglu Isleyen
OAOkan Aydın
Okan Aydın
MEMert Erciyestepe
Mert Erciyestepe
ASAbdullah Sakin
Abdullah Sakin
MAMuhammed Mustafa Atci
Muhammed Mustafa Atci
Background: Optimal multimodal treatment for esophagogastric junction adenocarcinoma remains debated. While the ESOPEC trial supports perioperative FLOT, real-world evidence is limited, particularly for Siewert type II tumors. Aim: To compare survival and treatment outcomes of perioperative FLOT versus definitive-dose chemoradiotherapy in non-metastatic Siewert II esophagogastric junction adenocarcinoma. Methods: Siewert type II esophagogastric junction adenocarcinoma was defined as tumors with an epicenter located between 1 cm above and 2 cm below the esophagogastric junction. We retrospectively identified patients with non-metastatic Siewert type II esophagogastric junction adenocarcinoma treated between January 2015 and December 2024 at three tertiary cancer centers. Patients received either perioperative FLOT chemotherapy or concurrent chemoradiotherapy with weekly carboplatin–paclitaxel and 50.4 Gy radiotherapy, delivered as definitive therapy or neoadjuvantly prior to planned surgery. Clinical characteristics, treatment delivery, pathological response, survival outcomes, and treatment-related toxicities were analyzed. Results: Seventy patients were included (FLOT, n=50; concurrent chemoradiotherapy, n=20). Surgery was performed in 45/50 (90%) FLOT patients and 7/20 (35%) concurrent chemoradiotherapy patients, representing a major difference between treatment groups. Median follow-up was 53.7 months. Median overall survival was 43.0 months in the FLOT group and 48.6 months in the concurrent chemoradiotherapy group (p=0.498). Median event-free survival was 34.2 months and 35.0 months, respectively (p=0.548). No pathological complete response occurred in the FLOT group; one patient (14.3%) in the concurrent chemoradiotherapy group achieved pathological complete response. Grade 3– 4 toxicities were more frequent with FLOT (26% vs. 5%). Distant relapse was the predominant recurrence pattern in both groups. Conclusion: Despite a substantial difference in surgical resection rates between groups, perioperative FLOT and concurrent chemoradiotherapy showed comparable survival outcomes in this real-world cohort of patients with Siewert type II EGJ adenocarcinoma. These findings should be interpreted with caution, as treatment selection and baseline differences may have influenced outcomes. Treatment decisions should be individualized based on patient characteristics and clinical context. Plain Language Summary: Siewert type II esophagogastric junction adenocarcinoma is a challenging disease with limited real-world comparative data. In this multicenter study, we compared two common treatment approaches: perioperative FLOT chemotherapy and chemoradiotherapy using a standard, full-course radiation treatment (50.4 Gy). Despite higher surgical rates in the FLOT group, survival outcomes were comparable between the two strategies. Pathological complete response was rare, and distant metastasis was the most common pattern of recurrence. FLOT was associated with higher grade 3– 4 toxicities. These findings suggest that treatment should be individualized, and that organ-preserving approaches such as chemoradiotherapy may be a reasonable option for selected patients with Siewert type II EGJ adenocarcinoma in clinical practice.